Canada markets closed

Ensysce Biosciences, Inc. (ENSC)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.5240-0.0300 (-5.42%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 4.11M
Enterprise Value 3.84M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.68
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.50

Trading Information

Stock Price History

Beta (5Y Monthly) 0.80
52-Week Change 3-82.79%
S&P500 52-Week Change 326.43%
52 Week High 33.2800
52 Week Low 30.5120
50-Day Moving Average 30.7148
200-Day Moving Average 31.1854

Share Statistics

Avg Vol (3 month) 3183.21k
Avg Vol (10 day) 391.06k
Shares Outstanding 57.59M
Implied Shares Outstanding 67.59M
Float 87.15M
% Held by Insiders 15.55%
% Held by Institutions 12.31%
Shares Short (Apr 15, 2024) 44.08k
Short Ratio (Apr 15, 2024) 40.04
Short % of Float (Apr 15, 2024) 40.06%
Short % of Shares Outstanding (Apr 15, 2024) 40.06%
Shares Short (prior month Mar 15, 2024) 456.53k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:12
Last Split Date 3Mar 31, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-612.72%

Management Effectiveness

Return on Assets (ttm)-155.91%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)2.23M
Revenue Per Share (ttm)0.99
Quarterly Revenue Growth (yoy)-64.10%
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-10.63M
Diluted EPS (ttm)-4.6900
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.12M
Total Cash Per Share (mrq)0.15
Total Debt (mrq)854.7k
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.69
Book Value Per Share (mrq)-0.10

Cash Flow Statement

Operating Cash Flow (ttm)-10.78M
Levered Free Cash Flow (ttm)-7.42M